Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

23.79 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 23.79
Bid (Size) 2.400 (2)
Ask (Size) 27.35 (1)
Prev. Close 23.79
Today's Range 23.79 - 23.79
52wk Range 12.24 - 26.04
Shares Outstanding 162,625,379
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Over $5M Bet On Southwest Gas? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire

Performance

YTD
+45.77%
+45.77%
1 Month
+9.38%
+9.38%
3 Month
+14.98%
+14.98%
6 Month
+62.17%
+62.17%
1 Year
+47.31%
+47.31%

More News

Read More
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Records 52-Week High Tuesday Morning
Via Investor Brand Network
ACADIA Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Top 5 Health Care Stocks That Should Keep You Up At Night
Via Benzinga
What 22 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
Via Benzinga
ACADIA Pharmaceuticals's Earnings: A Preview
Via Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
Via Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
Via Benzinga
Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment
Via Benzinga
1 Top Biotech Stock to Buy in March
Via The Motley Fool
Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting
From Acadia Pharmaceuticals Inc.
Via Business Wire
Why ACADIA Pharmaceuticals (ACAD) Shares Are Trading Higher
Via Benzinga
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Acadia Pharmaceuticals Inc.
Via Business Wire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug
Via Benzinga
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
Via Benzinga
3 Nasdaq Stocks on Watch This Week
Via The Motley Fool
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
From Acadia Pharmaceuticals Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.